Overexpression of ERG and wild-type PTEN are associated with favorable clinical prognosis and low biochemical recurrence in prostate cancer

PLoS ONE

Volumn 10, Issue 4, 2015, Pages

  Kim, Sung Han ^a   Kim, Soo Hee ^b   Joung, Jae Young ^a   Lee, Geon Kook ^a   Hong, Eun Kyung ^a   Kang, Kyung Min ^a   Yu, Ami ^a   Nam, Byung Ho ^a   Chung, Jinsoo ^a   Seo, Ho Kyung ^a   Park, Weon Seo ^a   Lee, Kang Hyun ^a  

^a National Cancer Center   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; ERG PROTEIN, HUMAN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PTEN PROTEIN, HUMAN; TRANSACTIVATOR PROTEIN; TRANSCRIPTION FACTOR ERG; TUMOR MARKER;

ADULT; AGED; ARTICLE; BIOCHEMICAL RECURRENCE FREE SURVIVAL; CANCER GROWTH; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CONTROLLED STUDY; ERG GENE; FOLLOW UP; GENE EXPRESSION PROFILING; GENE FUSION; GENE LOSS; GENE OVEREXPRESSION; GENETIC ASSOCIATION; GLEASON SCORE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KOREAN (PEOPLE); MAJOR CLINICAL STUDY; MALE; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; PROSTATECTOMY; PTEN GENE; RETROSPECTIVE STUDY; RISK FACTOR; VERY ELDERLY; ADENOCARCINOMA; DISEASE FREE SURVIVAL; GENE EXPRESSION; GENETICS; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PREVENTION AND CONTROL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROSTATIC NEOPLASMS; TUMOR RECURRENCE;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; DISEASE-FREE SURVIVAL; GENE EXPRESSION; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSTATIC NEOPLASMS; PTEN PHOSPHOHYDROLASE; TRANS-ACTIVATORS; TRANSCRIPTIONAL REGULATOR ERG;

EID: 84928254492     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0122498     Document Type: Article

References (41)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. International journal of cancer Journal international du cancer. 2010 Dec 15; 127(12):2893-917. PMID: 21351269. Epub 2011/02/26. eng. doi: 10.1002/ijc.25516
2. Rubin MA, Maher CA, Chinnaiyan AM. Common gene rearrangements in prostate cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2011 Sep 20; 29(27):3659-68. PMID: 21859993. Epub 2011/08/24. eng.
3. Tomlins SA, Palanisamy N, Siddiqui J, Chinnaiyan AM, Kunju LP. Antibody-based detection of ERG re-arrangements in prostate core biopsies, including diagnostically challenging cases: ERG staining in prostate core biopsies. Archives of pathology & laboratory medicine. 2012 Aug; 136(8):935-46. PMID: 22849743. Pubmed Central PMCID: PMC3667408. Epub 2012/08/02. eng.
4. Nagle RB, Algotar AM, Cortez CC, Smith K, Jones C, Sathyanarayana UG, et al. ERG overexpression and PTEN status predict capsular penetration in prostate carcinoma. The Prostate. 2013 Aug; 73(11):1233-40. PMID: 23653096. Pubmed Central PMCID: PMC4038303. Epub 2013/05/09. eng. doi: 10.1002/pros.22675
5. Carver BS, Tran J, Chen Z, Carracedo-Perez A, Alimonti A, Nardella C, et al. ETS rearrangements and prostate cancer initiation. Nature. 2009 Feb 12; 457(7231):E1; discussion E2-3. PMID: 19212347. Pubmed Central PMCID: 2967456. Epub 2009/02/13. eng. doi: 10.1038/nature07738
6. Perner S, Mosquera JM, Demichelis F, Hofer MD, Paris PL, Simko J, et al. TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion. The American journal of surgical pathology. 2007 Jun; 31(6):882-8. PMID: 17527075. Epub 2007/05/29. eng.
7. Saramaki OR, Harjula AE, Martikainen PM, Vessella RL, Tammela TL, Visakorpi T. TMPRSS2:ERG fusion identifies a subgroup of prostate cancers with a favorable prognosis. Clinical cancer research: an official journal of the American Association for Cancer Research. 2008 Jun 1; 14(11):3395-400. PMID: 18519769. Epub 2008/06/04. eng. doi: 10.1158/1078-0432.CCR-07-2051
8. Demichelis F, Fall K, Perner S, Andren O, Schmidt F, Setlur SR, et al. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene. 2007 Jul 5; 26(31):4596-9. PMID: 17237811. Epub 2007/01/24. eng.
9. Attard G, Clark J, Ambroisine L, Fisher G, Kovacs G, Flohr P, et al. Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer. Oncogene. 2008 Jan 10; 27(3):253-63. PMID: 17637754. Pubmed Central PMCID: 2646890. Epub 2007/07/20. eng.
10. Petrovics G, Liu A, Shaheduzzaman S, Furusato B, Sun C, Chen Y, et al. Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome. Oncogene. 2005 May 26; 24(23): 3847-52. PMID: 15750627. Epub 2005/03/08. eng.
11. Krohn A, Diedler T, Burkhardt L, Mayer PS, De Silva C, Meyer-Kornblum M, et al. Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer. The American journal of pathology. 2012 Aug; 181(2):401-12. PMID: 22705054. Epub 2012/06/19. eng. doi: 10.1016/j.ajpath.2012.04.026
12. Grupp K, Hohne TS, Prien K, Hube-Magg C, Tsourlakis MC, Sirma H, et al. Reduced CD147 expression is linked to ERG fusion-positive prostate cancers but lacks substantial impact on PSA recurrence in patients treated by radical prostatectomy. Experimental and molecular pathology. 2013 Oct; 95(2):227-34. PMID: 23948277. Epub 2013/08/21. eng. doi: 10.1016/j.yexmp.2013.08.002
13. Al Bashir S, Alshalalfa M, Hegazy SA, Dolph M, Donnelly B, Bismar TA. Cysteine- rich secretory protein 3 (CRISP3), ERG and PTEN define a molecular subtype of prostate cancer with implication to patients' prognosis. Journal of hematology & oncology. 2014; 7:21. PMID: 24606912. Pubmed Central PMCID: PMC3975646. Epub 2014/03/13. eng.
14. Carver BS, Tran J, Gopalan A, Chen Z, Shaikh S, Carracedo A, et al. Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nature genetics. 2009May; 41(5): 619-24. PMID: 19396168. Pubmed Central PMCID: 2835150. Epub 2009/04/28. eng. doi: 10.1038/ng.370
15. Epstein JI, Allsbrook WC Jr., Amin MB, Egevad LL. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. The American journal of surgical pathology. 2005 Sep; 29(9):1228-42. PMID: 16096414. Epub 2005/08/13. eng.
16. Vogel UF, Bueltmann BD. Simple, inexpensive, and precise paraffin tissue microarrays constructed with a conventional microcompound table and a drill grinder. American journal of clinical pathology. 2006 Sep; 126(3):342-8. PMID: 16880136. Epub 2006/08/02. eng.
17. Kim J, Yu J. Interrogating genomic and epigenomic data to understand prostate cancer. Biochimica et biophysica acta. 2012 Apr; 1825(2):186-96. PMID: 22240201. Pubmed Central PMCID: PMC3307852. Epub 2012/01/14. eng. doi: 10.1016/j.bbcan.2011.12.003
18. Cookson MS, Aus G, Burnett AL, Canby-Hagino ED, D'Amico AV, Dmochowski RR, et al. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. The Journal of urology. 2007 Feb; 177(2):540-5. PMID: 17222629. Epub 2007/01/16. eng.
19. Park K, Tomlins SA, Mudaliar KM, Chiu YL, Esgueva R, Mehra R, et al. Antibody-based detection of ERG rearrangement-positive prostate cancer. Neoplasia (New York, NY). 2010 Jul; 12(7):590-8. PMID: 20651988. Pubmed Central PMCID: 2907585. Epub 2010/07/24. eng.
20. Chaux A, Albadine R, Toubaji A, Hicks J, Meeker A, Platz EA, et al. Immunohistochemistry for ERG expression as a surrogate for TMPRSS2-ERG fusion detection in prostatic adenocarcinomas. The American journal of surgical pathology. 2011 Jul; 35(7):1014-20. PMID: 21677539. Pubmed Central PMCID: PMC3505676. Epub 2011/06/17. eng. doi: 10.1097/PAS.0b013e31821e8761
21. Suh JH, Park JW, Lee C, Moon KC. ERG immunohistochemistry and clinicopathologic characteristics in Korean prostate adenocarcinoma patients. Korean journal of pathology. 2012 Oct; 46(5):423-8. PMID: 23136568. Pubmed Central PMCID: PMC3490118. Epub 2012/11/09. eng. doi: 10.4132/KoreanJPathol.2012.46.5.423
22. van Leenders GJ, Boormans JL, Vissers CJ, Hoogland AM, Bressers AA, Furusato B, et al. Antibody EPR3864 is specific for ERG genomic fusions in prostate cancer: implications for pathological practice. Modern pathology: an official journal of the United States and Canadian Academy of Pathology, Inc. 2011 Aug; 24(8):1128-38. PMID: 21499236. Epub 2011/04/19. eng.
23. Falzarano SM, Zhou M, Hernandez AV, Klein EA, Rubin MA, Magi-Galluzzi C. Single focus prostate cancer: pathological features and ERG fusion status. The Journal of urology. 2011 Feb; 185(2): 489-94. PMID: 21167530. Epub 2010/12/21. eng. doi: 10.1016/j.juro.2010.09.093
24. Antonarakis ES, Keizman D, Zhang Z, Gurel B, Lotan TL, Hicks JL, et al. An immunohistochemical signature comprising PTEN, MYC, and Ki67 predicts progression in prostate cancer patients receiving adjuvant docetaxel after prostatectomy. Cancer. 2012 Dec 15; 118(24):6063-71. PMID: 22674438. Pubmed Central PMCID: PMC3572534. Epub 2012/06/08. eng. doi: 10.1002/cncr.27689
25. Hoogland AM, Jenster G, van Weerden WM, Trapman J, van der Kwast T, Roobol MJ, et al. ERG immunohistochemistry is not predictive for PSA recurrence, local recurrence or overall survival after radical prostatectomy for prostate cancer. Modern pathology: an official journal of the United States and Canadian Academy of Pathology, Inc. 2012 Mar; 25(3):471-9. PMID: 22080055. Epub 2011/11/15. eng.
26. Spencer ES, Johnston RB, Gordon RR, Lucas JM, Ussakli CH, Hurtado-Coll A, et al. Prognostic value of ERG oncoprotein in prostate cancer recurrence and cause-specific mortality. The Prostate. 2013 Jun; 73(9):905-12. PMID: 23334893. Pubmed Central PMCID: 3677047. Epub 2013/01/22. eng. doi: 10.1002/pros.22636
27. Bismar TA, Dolph M, Teng LH, Liu S, Donnelly B. ERG protein expression reflects hormonal treatment response and is associated with Gleason score and prostate cancer specific mortality. European journal of cancer (Oxford, England: 1990). 2012 Mar; 48(4):538-46. PMID: 22300588. Epub 2012/02/04. eng.
28. Kimura T, Furusato B, Miki J, Yamamoto T, Hayashi N, Takahashi H, et al. Expression of ERG oncoprotein is associated with a less aggressive tumor phenotype in Japanese prostate cancer patients. Pathology international. 2012 Nov; 62(11):742-8. PMID: 23121605. Epub 2012/11/06. eng. doi: 10.1111/pin.12006
29. Magi-Galluzzi C, Tsusuki T, Elson P, Simmerman K, LaFargue C, Esgueva R, et al. TMPRSS2-ERG gene fusion prevalence and class are significantly different in prostate cancer of Caucasian, African-American and Japanese patients. The Prostate. 2011 Apr; 71(5):489-97. PMID: 20878952. Epub 2010/09/30. eng. doi: 10.1002/pros.21265
30. Mosquera JM, Mehra R, Regan MM, Perner S, Genega EM, Bueti G, et al. Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States. Clinical cancer research: an official journal of the American Association for Cancer Research. 2009 Jul 15; 15(14): 4706-11. PMID: 19584163. Pubmed Central PMCID: 3717524. Epub 2009/07/09. eng. doi: 10.1158/1078-0432.CCR-08-2927
31. Mao X, Yu Y, Boyd LK, Ren G, Lin D, Chaplin T, et al. Distinct genomic alterations in prostate cancers in Chinese and Western populations suggest alternative pathways of prostate carcinogenesis. Cancer research. 2010 Jul 1; 70(13):5207-12. PMID: 20516122. Pubmed Central PMCID: 2896548. Epub 2010/06/03. eng. doi: 10.1158/0008-5472.CAN-09-4074
32. Minner S, Enodien M, Sirma H, Luebke AM, Krohn A, Mayer PS, et al. ERG status is unrelated to PSA recurrence in radically operated prostate cancer in the absence of antihormonal therapy. Clinical cancer research: an official journal of the American Association for Cancer Research. 2011 Sep 15; 17(18): 5878-88. PMID: 21791629. Epub 2011/07/28. eng. doi: 10.1158/1078-0432.CCR-11-1251
33. Verdu M, Trias I, Roman R, Rodon N, Garcia-Pelaez B, Calvo M, et al. ERG expression and prostatic adenocarcinoma. Virchows Archiv: an international journal of pathology. 2013 Jun; 462(6):639-44. PMID: 23703293. Epub 2013/05/25. eng. doi: 10.1007/s00428-013-1415-3
34. Sreenath TL, Dobi A, Petrovics G, Srivastava S. Oncogenic activation of ERG: A predominant mechanism in prostate cancer. Journal of carcinogenesis. 2011; 10:37. PMID: 22279422. Pubmed Central PMCID: 3263025. Epub 2012/01/27. eng. doi: 10.4103/1477-3163.91122
35. Furusato B, van Leenders GJ, Trapman J, Kimura T, Egawa S, Takahashi H, et al. Immunohistochemical ETS-related gene detection in a Japanese prostate cancer cohort: diagnostic use in Japanese prostate cancer patients. Pathology international. 2011 Jul; 61(7):409-14. PMID: 21707844. Epub 2011/06/29. eng. doi: 10.1111/j.1440-1827.2011.02675.x
36. Gronberg H. Prostate cancer epidemiology. Lancet. 2003 Mar 8; 361(9360):859-64. PMID: 12642065. Epub 2003/03/19. eng.
37. Sim HG, Cheng CW. Changing demography of prostate cancer in Asia. European journal of cancer (Oxford, England: 1990). 2005 Apr; 41(6):834-45. PMID: 15808953. Epub 2005/04/06. eng.
38. Yoshimoto M, Joshua AM, Cunha IW, Coudry RA, Fonseca FP, Ludkovski O, et al. Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome. Modern pathology: an official journal of the United States and Canadian Academy of Pathology, Inc. 2008 Dec; 21(12):1451-60. PMID: 18500259. Epub 2008/05/27. eng.
39. Han B, Mehra R, Lonigro RJ, Wang L, Suleman K, Menon A, et al. Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression. Modern pathology: an official journal of the United States and Canadian Academy of Pathology, Inc. 2009 Aug; 22(8):1083-93. PMID: 19407851. Pubmed Central PMCID: 2760294. Epub 2009/05/02. eng.
40. Leinonen KA, Saramaki OR, Furusato B, Kimura T, Takahashi H, Egawa S, et al. Loss of PTEN Is Associated with Aggressive Behavior in ERG-Positive Prostate Cancer. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2013 Nov 27. PMID: 24083995. Epub 2013/10/03. Eng.
41. Reid AH, Attard G, Brewer D, Miranda S, Riisnaes R, Clark J, et al. Novel, gross chromosomal alterations involving PTEN cooperate with allelic loss in prostate cancer. Modern pathology: an official journal of the United States and Canadian Academy of Pathology, Inc. 2012 Jun; 25(6):902-10. PMID: 22460813. Epub 2012/03/31. eng.